Literature DB >> 15517892

EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo.

Edi Levi1, Ramzi Mohammad, Udayini Kodali, Dorota Marciniak, Sudha Reddy, Amro Aboukameel, Fazlul H Sarkar, Omer Kucuk, Arun K Rishi, Adhip P N Majumdar.   

Abstract

BACKGROUND: EGF Receptor Related Protein (ERRP), a recently identified negative regulator of EGF-receptor (EGFR), has been shown to inhibit growth of colon cancer xenograft tumors in SCID mice. However, the mechanisms by which ERRP exerts its anti-tumor properties are poorly understood The current investigation was undertaken to delineate the inhibitory mechanisms that are triggered by ERRP.
MATERIALS AND METHODS: For in vivo experiments, recombinant ERRP (20 microg/mouse) or an equivalent volume of vehicle was injected (away from the tumor site) every other day for 10 days to SCID mice xenotransplanted with the colon cancer cell line HCT-116 Tumor explants were obtained for further immunohistochemical analysis. For in vitro studies, the HCT-116 cell line was incubated with recombinant ERRP and apoptosis markers and cell cycle changes were evaluated.
RESULTS: Recombinant ERRP caused marked inhibition of tumor growth. This was accompanied by increased apoptosis and attenuation of ERK1/2 and Akt activities. Exposure of HCT-116 cells to recombinant ERRP for 24 hours caused apoptosis and cell cycle arrest at G0/1-phase. Induction of apoptosis was evidenced by increased levels of cleaved caspase-3, PARP proteins and acridine orange staining.
CONCLUSION: Our findings reveal a pro-apoptotic property of ERRP both in vitro and in vivo. We propose that ERRP functions by inhibiting the activation of the EGF-receptor signaling and its downstream effectors such as ERK and Akt kinases, underscoring the potential of ERRP for the treatment of colorectal cancer where the EGF pathway is known to be activated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517892

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.

Authors:  Jyoti Nautiyal; Sanjeev Banerjee; Shailender S Kanwar; Yingjie Yu; Bhaumik B Patel; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

2.  ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.

Authors:  Jyoti Nautiyal; Yingjie Yu; Amro Aboukameel; Shailender S Kanwar; Jayanta K Das; Jianhua Du; Bhaumik B Patel; Fazlul H Sarkar; Arun K Rishi; Ramzi M Mohammad; Adhip P N Majumdar
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

Review 3.  Emerging therapies in gastrointestinal cancers.

Authors:  Jyoti Nautiyal; Arun K Rishi; Adhip P N Majumdar
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.